DSIJ Mindshare

Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

DSIJ Intelligence 0 190 Article rating: 5.0

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

Amid the heavy sell off, many quality midcaps, which have proven to be wealth creators for the investors in the past, have witnessed correction and are trading at low PE

DSIJ Intelligence 0 5866 Article rating: 3.8

With times like these, investors shouldn’t panic and keep a close eye on the fundamentally strong companies,

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR